You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CAR-macrophage

Showing 26 - 50 of 1,715
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Solid Tumor Trial in Shenyang (Intravenous infusion anti-HER2-CAR-T cell)

Not yet recruiting
  • Solid Tumor
  • Intravenous infusion anti-HER2-CAR-T cell
  • Shenyang, Liaoning, China
    Phase I Clinical Trials Center Of The First Hospital of China Me
Oct 30, 2023

Multiple Myeloma in Remission Trial in Shenzhen, Haikou (MM-specific universal CAR T cells)

Recruiting
  • Multiple Myeloma in Remission
  • MM-specific universal CAR T cells
  • Shenzhen, Guangdong, China
  • +1 more
Aug 23, 2023

Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma Trial in Dresden (MDC-CAR-BCMA001 (BCMA directed CAR

Not yet recruiting
  • Relapsed/Refractory Diffuse Large B-cell Lymphoma and Multiples Myeloma
  • MDC-CAR-BCMA001 (BCMA directed CAR T-cells)
  • Dresden, Germany
    Technische Universität Dresden, NCT/UCC, Early Clinical Trial Un
Apr 19, 2023

CNS Tumor, Pediatric, Glioma, Ependymoma Trial in Seattle (EGFR806-specific chimeric antigen receptor (CAR) T cell)

Active, not recruiting
  • Central Nervous System Tumor, Pediatric
  • +8 more
  • EGFR806-specific chimeric antigen receptor (CAR) T cell
  • Seattle, Washington
    Seattle Children's Hospital
Jan 18, 2023

Fibrinogen to Albumin Ratio and C-reactive Protein to Albumin

Not yet recruiting
  • Juvenile Idiopathic Arthritis
  • fibrinogen to albumin ratio (AFR) and C-reactive protein to albumin ratio (CAR)
  • (no location specified)
Aug 29, 2023

Multiple Myeloma Trial in United States (Talquetamab)

Recruiting
  • Multiple Myeloma
  • Basking Ridge, New Jersey
  • +6 more
Sep 27, 2023

Leukemia, Lymphoma Trial in United States (SCRI-CAR22v2)

Recruiting
  • Leukemia
  • Lymphoma
  • SCRI-CAR22v2
  • Los Angeles, California
  • +4 more
Jan 18, 2023

Carcinoma Trial (Intravenous infusion anti-CEA-CAR-T cell)

Not yet recruiting
  • Carcinoma
  • Intravenous infusion anti-CEA-CAR-T cell
  • (no location specified)
Aug 22, 2023

Safety and Efficacy of TCR-like CAR-T Trial in Nanjing (TCR-like CAR-T)

Recruiting
  • Safety and Efficacy of TCR-like CAR-T
  • TCR-like CAR-T
  • Nanjing, Jiangsu, China
    Zhongda hospital
Jul 26, 2023

Recurrent DLBCL, Refractory DLBCL Trial in Duarte (procedure, biological, radiation)

Not yet recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Biospecimen Collection
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Mar 24, 2023

Relapsed/Refractory Multiple Myeloma Trial in Philadelphia (Cevostamab)

Not yet recruiting
  • Relapsed/Refractory Multiple Myeloma
  • Philadelphia, Pennsylvania
    Hospital of the University of Pennsylvania
Apr 7, 2023

Acute Myeloid Leukemia Trial in Kunming (Anti-CLL1 CART cells)

Recruiting
  • Acute Myeloid Leukemia
  • Anti-CLL1 CART cells
  • Kunming, Yunnan, China
    No.212 Daguan Road, Xishan District
Nov 23, 2022

Multiple Myeloma Trial in Duarte (Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography)

Recruiting
  • Multiple Myeloma
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Sep 21, 2023

Hematologic Malignancies Trial in Zhengzhou (RD13-02 cell infusion)

Recruiting
  • Hematologic Malignancies
  • RD13-02 cell infusion
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jun 26, 2023

Head Neck Cancer, Relapse, Recurrent Trial in Chapel Hill (Cyclophosphamide, Fludarabine, Cell Therapy)

Not yet recruiting
  • Head and Neck Cancer
  • +3 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center at University of North Ca
Oct 18, 2023

Cytokine Release Syndrome Trial (CTO1681 10 µg, CTO1681 20 µg, CTO1681 30 µg)

Not yet recruiting
  • Cytokine Release Syndrome
  • CTO1681 10 μg
  • +2 more
  • (no location specified)
Jun 6, 2023

CNS Tumors, Atypical Teratoid/Rhabdoid Tumor, Diffuse Midline Glioma, H3 K27M-Mutant Trial in Memphis (B7-H3-CAR T cells)

Not yet recruiting
  • Central Nervous System Neoplasms
  • +6 more
  • B7-H3-CAR T cells
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Apr 18, 2023

Advanced Sarcoma Trial (NKG2D-CAR memory T cell)

Not yet recruiting
  • Advanced Sarcoma
  • NKG2D-CAR memory T cell
  • (no location specified)
Oct 17, 2023

B-Cell Non Hodgkin Lymphoma, B-Cell Acute Lymphoblastic Leukemia Trial in Hanoi (anti-CD19 CAR T-cells)

Recruiting
  • B-Cell Non Hodgkin Lymphoma
  • B-Cell Acute Lymphoblastic Leukemia
  • anti-CD19 CAR T-cells
  • Hanoi, Vietnam
    Vinmec Research Institute of Stem Cell and Gene Technology
Sep 5, 2023

Tumors, Hematologic Tumors, Hematologic Diseases Trial in Hefei (RD13-02 cell infusion)

Recruiting
  • Neoplasms
  • +2 more
  • RD13-02 cell infusion
  • Hefei, Anhui, China
    The First Affiliated Hospital of University of Science and Techn
Jun 5, 2023

Acute Lymphoblastic Leukemia, B-cell Lymphoma, Chronic Lymphocytic Leukemia Trial in Xuzhou (allogenic CD19-CAR-NK cells)

Recruiting
  • Acute Lymphoblastic Leukemia
  • +2 more
  • allogenic CD19-CAR-NK cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 11, 2023

Determining the Mechanisms of Loss of CAR T Cell Persistence

Not yet recruiting
  • Acute Lymphoblastic Leukemia With Failed Remission
  • +4 more
    • (no location specified)
    Mar 29, 2023

    Advanced or Metastatic Solid Tumors Trial in Beijing (CD40 ligand expressing MSLN-CAR T cells, Albumin-bound paclitaxel,

    Recruiting
    • Advanced or Metastatic Solid Tumors
    • CD40 ligand expressing MSLN-CAR T cells
    • +2 more
    • Beijing, Beijing, China
      Kaichao Feng
    Jan 19, 2023

    Tumors, Hematologic Tumors, Hematologic Diseases Trial in Xuzhou (RD13-02 cell infusion)

    Recruiting
    • Neoplasms
    • +2 more
    • RD13-02 cell infusion
    • Xuzhou, Jiangsu, China
      Affiliated hospital of Xuzhou medical college
    Jun 7, 2023

    Myasthenia Gravis Trial in Hangzhou (CD19 CAR-T cells injection)

    Recruiting
    • Myasthenia Gravis
    • CD19 CAR-T cells injection
    • Hangzhou, Zhejiang, China
      The first affiliated hospital of medical college of zhejiang uni
    Apr 12, 2023